Clinical trials: Hepatitis C, Chronic
Hepatitis C, Chronic, Hepatitis C
An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)
This is an observational study of patients undergoing treatment with PegIntron and Rebetol for chronic hepatitis C in clinical practice in Belgium. Treatment will not be administered as part of the study.
- Trial name
- PEGIMPACT (NCT00704756)
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908)
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Infection
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)
The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.
- Trial name
- NCT00874770
- Testing
- Daclatasvir, Peginterferon alpha-2a, ribavirin
- Where
- 14 sites in United States, France
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania
This study seeks to provide evidence of the effectiveness and obtain patient reported outcome (PRO) data for the interferon-free regimen of paritaprevir (PTV)/ritonavir (r) + ombitasvir (OBV), + dasabuvir (DSV), +/- ribavirin…
- Trial name
- NCT02807402
- Volunteers
- 522 people
- Sponsor
- AbbVie
Hepatitis C
Phase 3 Study of Sofosbuvir and Ribavirin
This study was to assess the safety and efficacy of sofosbuvir (GS-7977; PSI-7977) in combination with ribavirin (RBV) administered for 12 weeks compared with pegylated interferon (PEG)/RBV administered for 24 weeks in…
- Trial name
- FISSION (NCT01497366)
- Testing
- Sofosbuvir, PEG, RBV
- Where
- 97 sites in United States, Australia and 6 more
- Volunteers
- 527 people
- Sponsor
- Gilead Sciences
Hepatitis C Virus
Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) < Limit…
- Trial name
- Hallmark QUAD (NCT01573351)
- Testing
- Asunaprevir, Daclatasvir, Peg-interferon Alfa-2a
- Where
- 79 sites in United States, Argentina and 13 more
- Volunteers
- 398 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic, Hepatitis C
Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)
In patients with chronic hepatitis C, the ultimate treatment goal is the improvement of liver histology and inhibition of progression to liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT00787371
- Testing
- PegIntron (peginterferon alfa-2b)
- Volunteers
- 69 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 Infection
Primary objectives: The purpose of this study is to determine and compare the sustained virologic response (SVR, undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups.
- Trial name
- NCT01587586
- Testing
- PEGASYS 180 µg Q1W, P1101 180 µg Q1W, 48 doses, P1101 270µg Q1W, 48 doses
- Where
- 13 sites in Taiwan
- Volunteers
- 107 people
- Sponsor
- PharmaEssentia
Hepatitis C Virus
Ph IIA Study (SOC +/- NS5B)
At least 1 dose of BMS-791325 can be identified which is safe, well tolerated, and efficacious when combined with peg-interferon alfa-2a (pegIFNα-2a)/ribavirin (RBV) for the treatment of treatment-naïve, chronically-infected…
- Trial name
- HEPCAT (NCT01193361)
- Testing
- BMS-791325, Peg-interferon alfa-2a, Ribavirin
- Where
- 10 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C
The purpose of this study is to determine if 48 weeks of therapy with Pegylated Interferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Pegylated Interferon…
- Trial name
- NCT01447394
- Testing
- Pegylated Interferon Lambda, Pegylated Interferon Alfa-2a, Ribavirin
- Where
- 100 sites in United States, Canada and 18 more
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)
The primary purpose of this study is to compare the efficacy of two boceprevir (BOC)-containing therapeutic regimens in the treatment of naïve participants with chronic hepatitis C virus (HCV) genotype 1 who have the IL28B CC…
- Trial name
- NCT01544920
- Testing
- peg-Interferon alfa-2a, Ribavirin, Boceprevir
- Volunteers
- 737 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
The aim of this trial is to evaluate efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD Faldaprevir and RBV compared to a Telaprevir-based regimen along with PegIFN and RBV in chronically…
- Trial name
- NCT01858961
- Testing
- BI 201335, ribavirin, BI 207127
- Where
- 12 sites in Australia, Spain and 1 more
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic
A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C
This multicenter study will evaluate the correlation of interleukin 28B (IL28B) genotypes with disease characteristics and demographics in treatment-naïve and treatment-experienced chronic hepatitis C patients, including patients…
- Trial name
- NCT01675427
- Testing
- Interleukin 28B testing
- Where
- 210 sites in United States, Argentina and 29 more
- Volunteers
- 4,766 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus
Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection
To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.
- Trial name
- NCT01257204
- Testing
- Daclatasvir, Pegylated interferon alfa-2a, Ribavirin
- Where
- 26 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Safety and Efficacy Study to Compare Continuous Infusion of Interferon With Standard of Care for Chronic Hepatitis C
The purpose of the study is to evaluate if continuous subcutaneous delivery of interferon alfa-2b using an external drug pump in combination with the use of oral ribavirin provides a safe and effective treatment for patients with…
- Trial name
- COPE-HCV (NCT00919633)
- Testing
- interferon alfa-2b, peginterferon alfa-2b, ribavirin, USP
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- Medtronic Corporate Technologies and New Ventures
Hepatitis C, Chronic
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in…
- Trial name
- NCT01371578
- Testing
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Anemia
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
This single arm study will assess the safety of NeoRecormon in the correction of anemia in patients with chronic hepatitis C who are being treated with Pegylated interferon + ribavirin combination therapy.
- Trial name
- NCT00560274
- Testing
- Pegasys, Ribavirin, epoetin beta [NeoRecormon]
- Where
- 24 sites in France
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Thrombocytopenia
Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501
To evaluate the efficacy of E5501 by measuring platelet response in subjects with chronic hepatitis C virus (HCV)-related thrombocytopenia who require antiviral treatment.
- Trial name
- NCT01355289
- Testing
- Avatrombopag, Pegylated interferon (PEG-IFN), Telaprevir
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Eisai Inc.
Chronic Hepatitis C
A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
The purposes of this study are: to determine the safety and tolerability of multiple doses of A-831 at various doses to determine how multiple doses of A-831 are distributed through the bloodstream to determine if A-831 reduces…
- Trial name
- CP104 (NCT00522808)
- Testing
- A-831
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Arrow Therapeutics
Hepatitis C, Chronic, Hepacivirus
Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)
Study P05063 is a 3-year long-term follow-up (LTFU) study in participants previously treated with boceprevir (BOC) or narlaprevir (NAR) in a Phase 1, 2, or 3 clinical study.
- Trial name
- NCT00689390
- Testing
- Boceprevir, Narlaprevir, Peginterferon alfa-2b
- Volunteers
- 1,954 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)
This study will determine the efficacy of PEG-Intron (SCH 54031) in participants with chronic Hepatitis C virus (HCV) infection who have not been previously treated with interferon.
- Trial name
- NCT03537274
- Testing
- PEG-Intron, Interferon Alfa-2B
- Volunteers
- 1,224 people
- Sponsor
- Merck Sharp & Dohme LLC